Ritesh (Tesh) Khullar, Chief Commercial Officer

Ritesh (Tesh) Khullar was named as Chief Commercial Officer at Foundation Medicine in January 2020. With more than 20 years’ experience in oncology, he brings expertise in strategic commercialization and customer engagement to drive business growth and accelerate market development to support the Company’s leading comprehensive genomic profiling assays.

Our Proven Portfolio

Discover the only FDA-approved portfolio of comprehensive genomic profiling tests for all solid tumors. With FDA approvals for tissue- and blood-based tests, our portfolio can help guide treatment strategies for advanced cancer patients. 

Our comprehensive approach to next-generation sequencing and rigorous commitment to quality has set the industry standard. By partnering with biopharma and clinical stakeholders alike, we’ve developed an extensive genomic database and body of research that have strengthened the services we can offer all of our customers.

Learn more about our products and services for providers.

Our industry-leading testing and services bring in-depth genomic insights, experience, and a breadth of offerings into every practice to help predict patient benefit across multiple targeted therapies in multiple cancer indications.

Learn more about our Biopharma partnerships.

We provide actionable insights into the oncogenomics of both rare and common cancers, fueling discovery through commercialization by using a robust database and deep experience with FDA approvals.

FDA Approves Foundation Medicine's FoundationOne®Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test with Multiple Companion Diagnostic Indications for Patients with Advanced Cancer.

We are thrilled to announce the FDA approval of FoundationOne®Liquid CDx, FMI’s comprehensive liquid biopsy test, for all solid tumors. This approval is such an important milestone because we can now offer oncologists multiple FDA-approved, high-quality comprehensive genomic profiling options. From a simple blood draw, FoundationOne Liquid CDx can provide physicians and patients with molecular insights to inform treatment decisions whether that be targeted therapies, clinical trials or immunotherapy.   

For more about this approval, click here to read the press release.